Urticaria and Angioedema: Classification, Pathogenesis, and Stepwise Pharmacotherapy

Clinical Overview

Urticaria (hives) is a common cutaneous reaction characterized by transient erythematous wheals with central pallor and surrounding flare, typically accompanied by pruritus. Angioedema represents deeper dermal/subcutaneous swelling without central pallor, frequently involving lips, tongue, and pharynx. These conditions affect 20-25% of population at some point during lifetime, with 0.5-3% experiencing chronic urticaria lasting >6 weeks. Acute urticaria is usually self-limited and allergically mediated; chronic urticaria predominantly results from autoimmune mechanisms despite negative allergy testing in 90%.

Epidemiology

Acute urticaria: peak incidence childhood, but occurs across all ages. Triggers include medications (NSAIDs, ACE inhibitors, beta-lactam antibiotics), foods (shellfish, nuts, berries, eggs), infections (viral most common), latex, and insect stings. Resolution within 24 hours typical. Chronic urticaria: incidence 0.5-3% population, female predominance 2:1, peak age 40-50 years. Autoimmune chronic urticaria (60-80% of cases): self-perpetuating anti-IgE or anti-FcεRI-alpha antibodies activate mast cells independently of allergen. Idiopathic chronic urticaria (10-40%): mechanism unknown despite extensive investigation. Physical urticaria subtypes (dermographic, cold-induced, heat-induced, solar, cholinergic, aquagenic) represent 10-15% of chronic cases. Comorbid conditions: thyroid disease (20%), systemic lupus erythematosus (5%), Hashimoto thyroiditis (15%).

Pathophysiology

Acute urticaria: allergen/hapten cross-links IgE on mast cell surface, activating Fc-epsilon receptor 1 (FcεRI), triggering degranulation with histamine, tryptase, and other mediators. Histamine activates H1 receptors on endothelial cells, increasing vascular permeability through VE-cadherin disruption and gap junction opening. H2 receptors mediate additional vasodilation. Nitric oxide (NO) and bradykinin pathways amplify reaction. Lesions resolve when mediators cleared (typically 24 hours).

Chronic urticaria: autoimmune mechanism in 60-80% involves IgG autoantibodies against IgE or FcεRI-alpha, activating mast cells and basophils independent of allergen. Functionally indistinguishable from classical IgE-mediated activation: mast cell degranulation, histamine release, complement activation (C3a, C5a generation). Skin biopsy reveals minimal inflammation (non-vasculitic), with selective mast cell infiltration in dermis. Basophil activation test (BAT) detects elevated CD63 expression on basophils upon stimulation, confirming autoimmune activation in 55% of chronic urticaria. Persistent mast cell/basophil activation perpetuates symptom cycles. Thyroid autoimmunity (TPO antibodies) identified in 20%, suggesting systemic autoimmune tendency. IgE-mediated allergy testing negative in 90% of chronic cases.

Clinical Presentation

Acute urticaria: sudden onset wheals (mm to cm size) with central pallor and surrounding erythematous flare, intensely pruritic, typically appearing within minutes-hours of trigger exposure. Individual lesions resolve within 24 hours without residual markings (essential diagnostic feature). Angioedema development in 40%: deep subcutaneous/dermal edema producing localized swelling (lips, eyelids, tongue, pharynx), absence of flare, potentially dangerous if pharyngeal involvement compromises airway.

Chronic urticaria: daily or nearly-daily wheals persisting >6 weeks, varying intensity. Pruritus severe in 70%, interfering with sleep and daily activities. Angioedema develops in 40-50%. Lesion morphology identical to acute; however, continuous appearance distinguishes. No fixed lesion sites—lesions appear and resolve over hours but new lesions continuously develop. Triggers often unidentifiable despite investigation. Stress exacerbation in 80%, infections/NSAIDs in 30-40%, hormonal factors (menstrual cycle) in 35% of females.

Diagnosis

Diagnosis primarily clinical based on transient wheals + pruritus and history. Standard allergy testing unnecessary in chronic urticaria due to negative results in 90%; excessive testing promotes unnecessary dietary restriction and anxiety. Thyroid peroxidase (TPO) antibodies recommended given 20% prevalence and potential thyroid disease contribution. Basophil activation test (BAT) identifies autoimmune mechanism in specialized centers (55% positive in chronic urticaria) but not required for clinical management. Autologous serum skin test (ASST): patient's own serum induces wheal—50% sensitivity, 70% specificity for autoimmune urticaria; largely replaced by BAT. C1q precipitins for C1-inhibitor deficiency if angioedema dominant without urticaria (rare hereditary angioedema consideration). Physical urticaria diagnosed through provocative testing: dermographic (firm stroking), cold (ice cube challenge), heat, solar, or cholinergic (exercise challenge).

Treatment Algorithm

Acute Urticaria: First-generation H1-receptor antagonist (histamine blocker): cetirizine 10mg, fexofenadine 180mg, or loratadine 10mg once daily. Rapid symptom relief within 30-60 minutes. For refractory acute cases, add ranitidine 150-300mg twice daily (H2-antagonist) synergistic with H1 blocker. Avoid sedating first-generation antihistamines (diphenhydramine) except at bedtime for severe pruritus interfering with sleep. Parenteral epinephrine (0.3-0.5mg IM) mandatory for anaphylaxis/angioedema with airway compromise. Most acute cases resolve within 24-72 hours; continued antihistamine beyond acute phase unnecessary.

Chronic Urticaria—First-Line: Non-sedating H1-receptor antagonist (second-generation): cetirizine 10mg, fexofenadine 180mg, or loratadine 10mg once daily. Minimum 2-4 week trial before escalation. Efficacy 50-60% of chronic urticaria patients. Duration: continue while symptomatic; taper and discontinue after 2-4 weeks quiescence (remission occurs in 20-30% at 1-year follow-up).

Chronic Urticaria—Inadequate Response to H1 Antagonist: Escalate to higher H1 antagonist dose: cetirizine 10mg twice daily or fexofenadine 180mg twice daily (approved escalation per FDA 2007). Response rates increase to 65-75%. Continue 2-4 weeks before further escalation. Add ranitidine 150-300mg twice daily (H2-antagonist) if dose escalation monotherapy inadequate; combined H1/H2 efficacy superior.

Chronic Urticaria—Second-Line (Inadequate Response to High-Dose H1/H2): Omalizumab (anti-IgE monoclonal antibody): 300mg SC injection monthly. Requires baseline serum IgE <700 IU/mL. Particularly effective in autoimmune chronic urticaria (60-80% response rate vs. 45% idiopathic). Response onset 1-2 weeks; maximal benefit 4-6 weeks. Mechanism: cross-links and reduces surface IgE on mast cells/basophils, preventing their activation. Efficacy superior to cyclosporine in head-to-head trials. FDA-approved specifically for chronic idiopathic urticaria unresponsive to H1 antagonists.

Chronic Urticaria—Second-Line Alternatives: Cyclosporine 3-5 mg/kg/day (divided dosing) for omalizumab-ineligible or refractory patients; 50-60% response rate but slower onset (4-6 weeks) and significant toxicity (nephrotoxicity, hypertension, infection risk). Requires baseline and monthly renal function/BP monitoring. Duration usually 6-12 months. Intravenous immunoglobulin (IVIG) 2g/kg monthly: 50% of autoimmune urticaria respond; mechanism unclear. Limited by cost and infusion reactions. Mycophenolate mofetil 1-1.5g twice daily: emerging agent, 50% response in uncontrolled studies; off-label use.

Angioedema Management: Angioedema without urticaria or with airway compromise requires urgent intervention. Epinephrine IM 0.3-0.5mg for acute severe angioedema/anaphylaxis. Airway assessment mandatory; prepare for intubation if pharyngeal/tongue involvement. Consider C1q precipitins and C4 levels if recurrent angioedema without urticaria (hereditary angioedema consideration; requires C1-inhibitor replacement therapy distinct from urticaria management).

Prognosis

Acute urticaria: 90% resolve within 24 hours with antihistamine therapy or spontaneously. Chronic urticaria: 20-30% achieve spontaneous remission within 1 year without treatment; however, most require ongoing therapy. Omalizumab achieves 60-80% symptom control in autoimmune disease. Long-term (>5 years) remission off all therapy occurs in 30-40% of chronic urticaria. Early omalizumab initiation and adequate dosing improve remission likelihood. Prognosis worse in patients with concurrent thyroid disease, systemic lupus, or delayed-pressure urticaria (physical subtype).

When to See a Dermatologist

Refer for: chronic urticaria (>6 weeks), inadequate response to first-line H1 antagonists, consideration of omalizumab therapy, diagnostic uncertainty, or complex angioedema. Dermatologists coordinate with allergy/immunology for difficult cases, manage omalizumab therapy, and address quality-of-life impact.

Frequently Asked Questions

Q: What's causing my hives if allergy tests are negative?
A: Most chronic urticaria (60-80%) is autoimmune—your own immune system attacks skin cells, independent of external allergens. This explains negative allergy tests. Omalizumab specifically targets autoimmune mechanism, providing superior efficacy.

Q: Do I need to avoid certain foods?
A: Unnecessary dietary restriction recommended for negative allergy testing. However, if specific food consistently triggers flares (reproducible response), reasonable avoidance. Excessive testing and elimination diets promote anxiety without clear benefit; avoid this approach.

Q: Will antihistamines stop working?
A: Tachyphylaxis (reduced effectiveness over time) occurs in <5% of patients. Standard practice: continue regular dosing; increasing dose more effective than cycling medications. Omalizumab maintains efficacy long-term without tachyphylaxis development.

Q: How long will I need to take medication?
A: Acute urticaria: typically 24-48 hours. Chronic urticaria: variable; many achieve remission 1-3 years after initiation. Omalizumab therapy continued for 3-6 months minimum; some require long-term maintenance (>12 months). Discontinuation after remission attempted; 30-40% relapse requiring reinitiation.

References